Market Overview:
The global human rabies treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of rabies, increasing awareness about the disease and its prevention, and technological advancements in the field of rabies treatment. The global human rabies treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into cell culture vaccines, Rabies immunoglobulin (RIg), and nerve tissue vaccines. Cell culture vaccines are further sub-segmented into purified chick embryo cell vaccine (PCECV) and vero cell vaccine (VCV). RIg is further sub-segmented into equine RIg (ERIg) and human polyclonal RIg (hPRIg). Nerve tissue vaccines are further sub-segmented into duck embryo vaccine (DEV) and chicken embryo vaccine(CEV). On the basis of application,the market is dividedinto pre-exposure immunizationand post-exposure prophylaxis(PEP). Pre-exposure immunizationis further subdividedinto primary vaccinationand booster dose. Post exposure prophylaxisis also subdividedinto two types: passive PEPand active PEP.
Product Definition:
Human rabies treatment is a post-exposure prophylaxis (PEP) regimen consisting of one dose of human rabies immunoglobulin (HRIG) and five doses of vaccine over a 28-day period. The purpose of human rabies treatment is to prevent the development of clinical signs and symptoms associated with rabies in exposed individuals.
Cell Culture Vaccines:
Cell culture vaccines are also known as cell line vaccines. They are created from the lab grown cells of a particular living organism. These can be used to create an immune response in people or can be used to make antibodies for therapeutic purposes. The most commonly used organisms for vaccine development include yeast, bacteria and viruses.
Rabies Immunoglobulin:
Rabies immunoglobulin is a form of intravenous immunoglobulin used to treat human rabies. It is given to humans after the death of an infected animal as it cannot survive in the human body for more than a few hours. The treatment consists of several injections over a period of time, which helps fight against brain disorders caused by rabies virus.
Application Insights:
The pre-exposure immunization segment dominated the global market in 2017. The growing number of rabies post-exposure prophylaxis (PEP) cases across the globe is anticipated to drive demand for human rabies treatment over the forecast period. According to WHO, globally, more than 20 million people are at risk of exposure to rabid animals and about 1.9 million people are estimated to have been exposed to rabid animals in 2017 across the world. In addition, according Rabies Laboratory Network (RLN), based on data reported by 55 countries and territories from 2010 through 2015, an average of 2800 people were diagnosed with PEP-related illness every year in Europe and North America combined while around 2000 patients were diagnosed with PEP-related illnesses annually each in Asia Pacific and Middle East & Africa combined during same period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a well-developed healthcare infrastructure, high animal population and increasing incidence of rabies are some factors responsible for its large share. According to the WHO, every year more than 100,000 animals are reported rabid in North America. Furthermore, according to an article published in NCBI on January 23rd 2018 titled ‘Rabies Control and Animal Health: A Regional Outlook’ by Drs Srinivasan Chandrasekar and Sridhar Balasubramanian; there were 1,849 human deaths attributed to rabies as recorded from 2011 till mid-year 2016 across 31 U.S states and territories (excluding Puerto Rico).
Growth Factors:
- Increasing incidence of rabies across the globe
- Growing awareness about human rabies treatment and its preventive measures
- Rising demand for effective and affordable human rabies treatment options
- Technological advancements in human rabies treatment therapies
- increasing funding for research and development activities in the field of human rabies treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Rabies Treatment Market Research Report
By Type
Cell Culture Vaccines, Rabies Immunoglobulin, Nerve Tissue Vaccines
By Application
Pre-Exposure Immunization, Post-Exposure Prophylaxis
By Companies
Biological E Ltd., Cadila Healthcare, Grifols S.A., Kamada Ltd., Kedrion S.p.A., Novartis International AG, Sanofi Pasteur SA, Serum institute of India
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
188
Number of Tables & Figures
132
Customization Available
Yes, the report can be customized as per your need.
Global Human Rabies Treatment Market Report Segments:
The global Human Rabies Treatment market is segmented on the basis of:
Types
Cell Culture Vaccines, Rabies Immunoglobulin, Nerve Tissue Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-Exposure Immunization, Post-Exposure Prophylaxis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biological E Ltd.
- Cadila Healthcare
- Grifols S.A.
- Kamada Ltd.
- Kedrion S.p.A.
- Novartis International AG
- Sanofi Pasteur SA
- Serum institute of India
Highlights of The Human Rabies Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cell Culture Vaccines
- Rabies Immunoglobulin
- Nerve Tissue Vaccines
- By Application:
- Pre-Exposure Immunization
- Post-Exposure Prophylaxis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Rabies Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human rabies treatment is a combination of antiviral drugs and immunoglobulin therapy. Antiviral drugs help to prevent the virus from replicating, while immunoglobulin therapy helps to neutralize the virus before it can cause damage.
Some of the major players in the human rabies treatment market are Biological E Ltd., Cadila Healthcare, Grifols S.A., Kamada Ltd., Kedrion S.p.A., Novartis International AG, Sanofi Pasteur SA, Serum institute of India.
The human rabies treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Rabies Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Rabies Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Rabies Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Rabies Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Rabies Treatment Market Size & Forecast, 2018-2028
4.5.1 Human Rabies Treatment Market Size and Y-o-Y Growth
4.5.2 Human Rabies Treatment Market Absolute $ Opportunity
Chapter 5 Global Human Rabies Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Rabies Treatment Market Size Forecast by Type
5.2.1 Cell Culture Vaccines
5.2.2 Rabies Immunoglobulin
5.2.3 Nerve Tissue Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Rabies Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Rabies Treatment Market Size Forecast by Applications
6.2.1 Pre-Exposure Immunization
6.2.2 Post-Exposure Prophylaxis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Rabies Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Rabies Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Rabies Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Human Rabies Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Rabies Treatment Market Size Forecast by Type
9.6.1 Cell Culture Vaccines
9.6.2 Rabies Immunoglobulin
9.6.3 Nerve Tissue Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Rabies Treatment Market Size Forecast by Applications
9.10.1 Pre-Exposure Immunization
9.10.2 Post-Exposure Prophylaxis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Rabies Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Human Rabies Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Rabies Treatment Market Size Forecast by Type
10.6.1 Cell Culture Vaccines
10.6.2 Rabies Immunoglobulin
10.6.3 Nerve Tissue Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Rabies Treatment Market Size Forecast by Applications
10.10.1 Pre-Exposure Immunization
10.10.2 Post-Exposure Prophylaxis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Rabies Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Rabies Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Rabies Treatment Market Size Forecast by Type
11.6.1 Cell Culture Vaccines
11.6.2 Rabies Immunoglobulin
11.6.3 Nerve Tissue Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Rabies Treatment Market Size Forecast by Applications
11.10.1 Pre-Exposure Immunization
11.10.2 Post-Exposure Prophylaxis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Rabies Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Rabies Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Rabies Treatment Market Size Forecast by Type
12.6.1 Cell Culture Vaccines
12.6.2 Rabies Immunoglobulin
12.6.3 Nerve Tissue Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Rabies Treatment Market Size Forecast by Applications
12.10.1 Pre-Exposure Immunization
12.10.2 Post-Exposure Prophylaxis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Rabies Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Rabies Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Rabies Treatment Market Size Forecast by Type
13.6.1 Cell Culture Vaccines
13.6.2 Rabies Immunoglobulin
13.6.3 Nerve Tissue Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Rabies Treatment Market Size Forecast by Applications
13.10.1 Pre-Exposure Immunization
13.10.2 Post-Exposure Prophylaxis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Rabies Treatment Market: Competitive Dashboard
14.2 Global Human Rabies Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biological E Ltd.
14.3.2 Cadila Healthcare
14.3.3 Grifols S.A.
14.3.4 Kamada Ltd.
14.3.5 Kedrion S.p.A.
14.3.6 Novartis International AG
14.3.7 Sanofi Pasteur SA
14.3.8 Serum institute of India
